Description

Acarbose Tablets are alpha-glucosidase inhibitors commonly used in experimental models studying postprandial glucose control, carbohydrate digestion, and type 2 diabetes mellitus (T2DM). These tablets delay glucose absorption from the intestine by inhibiting enzymes that break down complex carbohydrates, making them essential in metabolic and pharmacological research.

Manufactured by Beijing Jingfeng Pharmaceutical Group Co., Ltd., this formulation is approved under NMPA approval number H20233870 and offered in a 50mg strength.

?? For laboratory and research use only. Not for clinical, diagnostic, or therapeutic purposes.

Product Parameters

Mechanism & Research Applications

Acarbose is a reversible inhibitor of intestinal alpha-glucosidases, such as maltase and sucrase. It reduces the digestion of complex carbohydrates into glucose, resulting in delayed and reduced postprandial blood glucose levels.

Research uses include:

• Experimental models of type 2 diabetes mellitus (T2DM)

• Investigations into carbohydrate absorption and metabolism

• Studies on alpha-glucosidase enzyme activity

• Combination therapy research with insulin or oral antidiabetics

Observed Effects in Research

In lab-based studies, Acarbose has shown:

• Reduced post-meal glucose spikes

• Altered gut microbiota profile

• Delayed glucose absorption in intestinal tissue

• Synergistic effects when used with metformin or insulin analogs

• Improvement in glycemic control markers in T2DM models

Safety & Handling

• Use: Laboratory/Research use only

• PPE: Wear lab coat, gloves, and eye protection

• Storage: Store below 25°C in original packaging

• Disposal: Dispose of in accordance with laboratory chemical waste protocols

Research Use Disclaimer

This product is strictly for laboratory research purposes only. It is not for use in humans or animals. Misuse of this product may violate local or international regulations. Use only in approved research settings.